Hua Medicine (HKSE:02552) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Dec. 14, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Hua Medicine's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Hua Medicine's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hua Medicine's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Hua Medicine's Future 3-5Y EPS without NRI Growth Rate falls into.

Hua Medicine (HKSE:02552) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Hua Medicine Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Hua Medicine's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hua Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Traded in Other Exchanges

HUMDF:USA

Address

Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203

Website

https://www.huamedicine.com

Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.

Executives

Hlyy Limited	2306 Nominee for another person
Tct (bvi) Limited	2501 Other
The Core Trust Company Limited	2301 Trustee
Hong Jane Xingfang	2202 Interest of your spouse
Chen Li	2101 Beneficial owner
Wuxi Pharmatech Investments (cayman) Inc.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Investment Holdings (cayman) Inc.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Fund I General Partner L.p.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Healthcare Fund I L.p.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.	2201 Interest of corporation controlled by you
Wuxi Apptec International Holdings Limited	2201 Interest of corporation controlled by you
Nelsen Robert Taylor	2101 Beneficial owner
Venrock Management V, Llc	2102 Investment manager
Harvest Yuanxiang (cayman) Limited	2101 Beneficial owner
Arch Venture Fund Vii, L.p.	2101 Beneficial owner

Hua Medicine Headlines

No Headlines